MNPR_OUT_1 [2025-04-02 12:30:12 -0400] 3133 Bytes | 886 tokens | Cum: 886 tkns (11.07% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Monopar Therapeutics (MNPR) hit my radar screen, up to 39.4 from a prev close of 33.43 Do you think its got more juice or is it lacking potential? It's 12:30:11 PM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Monopar Therapeutics (MNPR)
IPO: 2019-12-19 (5 Years Ago)
Market Cap: $204,007,511
Shares Outstanding: 6,100,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Here's the first list of news for Monopar Therapeutics:

C1 - Mar-31-25 08:00AM - Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
C2 - Mar-21-25 08:50AM - Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
C3 - Feb-03-25 07:22PM - Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025
C4 - Jan-23-25 01:10PM - Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
C5 - Jan-23-25 01:10PM 07:06AM - Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright
C6 - Dec-31-24 02:36AM - These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year Heres What Analysts Expect in 2025
C7 - Dec-20-24 09:00AM - Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
C8 - Dec-05-24 04:21PM - Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Prior AI Reports for MNPR:
1. 2025-03-19 – Score: 65 – Target: 45.0000 – Highs: 42.9600 / 47.8252 / 46.00
strong-quarter-performance-amidst-negative-roi-and-roe

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Monopar Therapeutics (MNPR)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

MNPR_OUT_3 [2025-04-02 12:30:16 -0400] 1101 Bytes | 322 tokens | Cum: 1210 tkns (15.12% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments**
Date: Mar-31-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052236/0/en/Monopar-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Developments.html

March 31, 2025 08:00 ET| Source:Monopar Therapeutics Inc.Monopar Therapeutics Inc.

WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments.

“2024 was a productive year for Monopar, with the in-licensing of ALXN1840, the initiation of two first-in-human radiopharma Phase 1 clinical trials, and the strengthening

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MNPR_OUT_5 [2025-04-02 12:30:22 -0400] 1113 Bytes | 272 tokens | Cum: 1569 tkns (19.61% of 8k)
==========================================================================

Showing C1 (chunk 2 of 10): of our balance sheet with net proceeds of over $55 million from financings,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “We are especially grateful to the Wilson disease patients. Their testimonies and support are what provided the opportunity for Monopar to progress ALXN1840 toward an NDA filing.”

ALXN1840–Plan to Submit NDA with FDA for Wilson Disease in Early 2026

Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in tissues and organs such as the liver and brain. ALXN1840 is a potent binder and mobilizer of copper, as demonstrated in a Phase 3 clinical trial that met its primary endpoint. In October 2024, Monopar announced the execution of a worldwide exclusive license to ALXN1840 with Alexion, AstraZeneca Rare Disease (“AZ”). As part of t

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MNPR_OUT_7 [2025-04-02 12:30:22 -0400] 926 Bytes | 268 tokens | Cum: 1936 tkns (24.20% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T12:02:07Z - HC Wainwright Reiterates "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)...
A2 - 2025-04-01T20:11:26Z - Monopar Therapeutics...
A3 - 2025-03-31T12:13:46Z - Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments | Taiwan...
A4 - 2025-03-31T12:00:00Z - Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments - Monopa...
A5 - 2025-03-31T12:07:05Z - Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MNPR_OUT_9 [2025-04-02 12:30:28 -0400] 1098 Bytes | 318 tokens | Cum: 2256 tkns (28.20% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**HC Wainwright Reiterates "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)**Date: 2025-04-02Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/hc-wainwright-reiterates-buy-rating-for-monopar-therapeutics-nasdaqmnpr-2025-04-01/Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 9.86% from the company's current price.

Separately, Piper Sandler reiterated an "overweight" rating and issued a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th.

View Our Latest Report on Monopar Therapeutics

NASDAQ MNPR opened at $36.4

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MNPR_OUT_11 [2025-04-02 12:30:28 -0400] 884 Bytes | 287 tokens | Cum: 2654 tkns (33.17% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-08T13:00:00Z - Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
B2 - 2024-10-29T01:15:00Z - Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
B3 - 2024-06-25T12:00:00Z - Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
B4 - 2024-06-11T11:30:00Z - Monopar and NorthStar Amend & Extend Collaboration
B5 - 2024-05-24T12:00:00Z - Monopar Announces CFO Succession
B6 - 2024-05-17T13:55:03Z - Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MNPR_OUT_13 [2025-04-02 12:30:33 -0400] 757 Bytes | 212 tokens | Cum: 2868 tkns (35.85% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/08/2977596/0/en/Monopar-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Developments.htmlMonopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MNPR_OUT_15 [2025-04-02 12:30:34 -0400] 812 Bytes | 197 tokens | Cum: 3177 tkns (39.71% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond

On March 31, 2025, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of this press release is attached hereto as Exhibit ...

S2 - 2025-03-31 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing at the e...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MNPR_OUT_17 [2025-04-02 12:30:40 -0400] 961 Bytes | 242 tokens | Cum: 3421 tkns (42.76% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition

On March 31, 2025, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MNPR_OUT_19 [2025-04-02 12:30:56 -0400] 5375 Bytes | 1579 tokens | Cum: 5129 tkns (64.11% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+----------------------+------------------------+------------------------+
| Volume: 52,292 | Perf Month: 27.22% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+----------------------+------------------------+------------------------+
| Avg Volume: 51.26K | Perf Quarter: 69.10% | Short Float: 1.29% | ROE: -51.42% |
+--------------------+----------------------+------------------------+------------------------+
| Rel Volume: 2.26 | Index: - | Short Ratio: 0.99 | ROI: -28.32% |
+--------------------+----------------------+------------------------+------------------------+
| RSI (14): 55.34 | Market Cap: 246.52M | Short Interest: 0.05M | Sales Surprise: - |
+--------------------+----------------------+------------------------+------------------------+
| ATR (14): 5.54 | Shs Outstand: 6.10M | Beta: 1.16 | EPS Surprise: -149.09% |
+--------------------+----------------------+------------------------+------------------------+
| SMA20: 14.52% | Shs Float: 3.93M | Sales Q/Q: - | P/E: - |
+--------------------+----------------------+------------------------+------------------------+
| SMA50: 4.82% | Inst Own: 42.25% | Sales past 5Y: 0.00% | Earnings: Mar 31 BMO |
+--------------------+----------------------+------------------------+------------------------+
| SMA200: 126.39% | Insider Own: 35.63% | Employees: 16 | |
+--------------------+----------------------+------------------------+------------------------+
| Perf Week: 5.85% | Insider Trans: 0.07% | Debt/Eq: 0.00 | |
+--------------------+----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Monopar Therapeutics (MNPR) by Robinson Chandler (Chief Executive Officer) on 2025-03-04
- Common Stock: 6002 shares at $N/A (D)
- Common Stock: 1759 shares at $31.7 (D)
- Stock Options: 85759 shares at $0 (D)
- Restricted Stock Units: 79899 shares at $0 (D)
- Restricted Stock Units: 6002 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Cittadine Andrew (Chief Operating Officer) on 2025-03-04
- Stock Options: 43445 shares at $0 (D)
- Restricted Stock Units: 40581 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by STARR CHRISTOPHER M (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by KLAUSNER ARTHUR J (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Anderson Raymond (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Talukdar Lavina (Unknown Title) on 2025-03-04
- Stock Options: 5683 shares at $0 (D)

Inside Trans: Monopar Therapeutics (MNPR) by Tsuchimoto Kim R (Unknown Title) on 2025-03-04
- Stock Options: 11365 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1304276.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 39.005
Average Volume: 32464.52
30-Day High: 44.74
30-Day Low: 27.95

[Detailed Financials: Q3 2024]
- Total Assets: $6,069,654.0
- Total Liabilities: $1,122,867.0
- Total Equity: $4,946,787.0
- Current Assets: $6,069,654.0
- Current Liabilities: $1,122,867.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-3,259,732.0

[Detailed Financials: Q2 2024]
- Total Assets: $7,179,788.0
- Total Liabilities: $1,089,462.0
- Total Equity: $6,090,325.0
- Current Assets: $7,179,788.0
- Current Liabilities: $-6,090,325.0

[Income Statement: Q2 2024]
- Revenue: $73,475.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,689,140.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

MNPR_OUT_21 [2025-04-02 12:30:58 -0400] 676 Bytes | 167 tokens | Cum: 5544 tkns (69.30% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

MNPR_IN_23 [2025-04-02 12:30:59 -0400] 126 Bytes | 29 tokens | Cum: 5601 tkns (70.01% of 8k)
==========================================================================

====================================
[2025-04-02 12:30:59] # Analysis Completed
Elapsed Time: 47.46 seconds